Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment